Serum adropin level and ENHO gene expression in systemic sclerosis

dc.contributor.authorYolbas, Servet
dc.contributor.authorKara, Murat
dc.contributor.authorYilmaz, Musa
dc.contributor.authorAydin, Suleyman
dc.contributor.authorKoca, Suleyman Serdar
dc.date.accessioned2026-08-12T17:32:50Z
dc.date.issued2016
dc.departmentFırat Üniversitesi
dc.descriptionAnnual Meeting of Spondyloarthritis-Research-and-Treatment-Network (SPARTAN) -- JUL 25-26, 2015 -- Denver, CO
dc.description.abstractAdropin, a secreted protein, is encoded by the energy homeostasis associated (ENHO) gene. It has been implicated in the several physiological and pathological processes such as angiogenesis and apoptosis. Therefore, the aim of present study was to investigate serum adropin levels and ENHO gene expressions in systemic sclerosis (SSc) characterized by vasculopathy, inflammation, and progressive fibrosis of the skin and internal organs. The study includes 27 patients with SSc, 39 patients with Beh double dagger et's disease (BD), and 20 healthy controls (HC). Serum adropin levels and ENHO gene expressions by peripheral blood mononuclear cells were analyzed by ELISA method and by real-time PCR, respectively. The serum adropin levels were higher in the SSc and BD groups than in the HC group (p = 0.023 and p < 0.001, respectively). However, there were no significant differences among the groups in terms of ENHO gene expressions (p (ANOVA) = 0.149). There was no significant difference between the limited and diffuse cutaneous subtypes of SSc in terms of serum adropin level and ENHO gene expression. Moreover, serum adropin level and ENHO gene expression were not associated with the disease activity and severity indexes. ENHO gene expression was correlated with the triglyceride levels in the BD group (r = -0.426, p = 0.027). The augmented serum adropin levels may be expected in the chronic inflammatory disease and seem not to be characteristic of only SSc. However, further studies are needed to explain the precise role of adropin in SSc.
dc.description.sponsorshipSpondyloarthritis Res & Treatment Network
dc.identifier.doi10.1007/s10067-016-3266-1
dc.identifier.endpage1540
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue6
dc.identifier.orcid0000-0001-9557-678X
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid27079850
dc.identifier.scopus2-s2.0-84963742711
dc.identifier.scopusqualityQ1
dc.identifier.startpage1535
dc.identifier.urihttps://doi.org/10.1007/s10067-016-3266-1
dc.identifier.urihttps://hdl.handle.net/11508/56792
dc.identifier.volume35
dc.identifier.wosWOS:000376281000018
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer London Ltd
dc.relation.ispartofClinical Rheumatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectAdropin
dc.subjectBehcet's disease
dc.subjectENHO
dc.subjectSystemic sclerosis
dc.titleSerum adropin level and ENHO gene expression in systemic sclerosis
dc.typeConference Object

Dosyalar